Samuel Rabkin
Professor of Neurosciences Harvard Medical School
Seminars
            Wednesday 28th January 2026
        
        Integrating Oncolytic Viruses with DDR Inhibitors to Drive Progress in Glioblastoma Therapy
    
    
        
            3:45 pm
            
        
    
    • Highlighting oncolytic herpes simplex virus (oHSV) combinations with DDR inhibitors that synergize in treating glioblastoma
• Using patient-derived human and mouse glioblastoma stem-like cells (GSCs) as representative preclinical models to assess therapy
• Targeting cancer stem cells with DNA-PK inhibitors and oHSV
 
					